Cyclodextrins, Blood-Brain Barrier, and Treatment of Neurological Diseases

Archives of Medical Research

Volumn 45, Issue 8, 2014, Pages 711-729

  Vecsernyés, Miklós ^a   Fenyvesi, Ferenc ^a   Bácskay, Ildikó ^a   Deli, Mária A ^b   Szente, Lajos ^c   Fenyvesi, Éva ^c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c CycloLab Cyclodextrin Research & Development Laboratory Ltd   (Hungary)

Author keywords

Blood brain barrier; CNS diseases; Cyclodextrins; Drug delivery; Tight junctions

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ABC TRANSPORTER; CYCLODEXTRIN; EXCIPIENT; NANOPARTICLE; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; BRAIN TUMOR; CARDIOVASCULAR SYSTEM; CELL INTERACTION; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CENTRAL NERVOUS SYSTEM INFECTION; DEGENERATIVE DISEASE; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG PENETRATION; DRUG TRANSPORT; ENDOCYTOSIS; ENDOTHELIUM CELL; EPILEPSY; HUMAN; IMMUNE SYSTEM; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LYSOSOME STORAGE DISEASE; NEUROLOGIC DISEASE; NIEMANN PICK DISEASE; NONHUMAN; NOSE MUCOSA; REPERFUSION INJURY; REVIEW; SKIN PENETRATION; TIGHT JUNCTION; ANIMAL; BRAIN NEOPLASMS; DRUG EFFECTS; METABOLISM; MOUSE; NEURODEGENERATIVE DISEASES; NIEMANN-PICK DISEASE, TYPE C; STROKE; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CYCLODEXTRINS; EXCIPIENTS; HUMANS; MICE; NANOPARTICLES; NEURODEGENERATIVE DISEASES; NIEMANN-PICK DISEASE, TYPE C; STROKE;

EID: 84924765346     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.11.020     Document Type: Review

References (212)

1. Pardridge W.M. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012, 32:1959-1972.
2. Deli M.A. Drug transport and the blood-brain barrier. Solubility, Delivery, and ADME Problems of Drugs and Drug-Candidates 2011, 144-165. Bentham Science Publishers Ltd., Washington. K. Tihanyi, M. Vastag (Eds.).
3. Loftsson T., Vogensen S.B., Brewster M.E., et al. Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci 2007, 96:2532-2546.
4. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. JPharm Pharmacol 2011, 63:1119-1135.
5. Szejtli J. Cyclodextrin Technology 1988, Kluwer, Dordrecht.
6. Comprehensive Supramolecular Chemistry, Volume 3: Cyclodextrins 1996, Pergamon, Oxford, UK. J. Szejtli, T. Osa (Eds.).
7. Giordano F., Novak C., Moyano J.R. Thermal analysis of cyclodextrins and their inclusion compounds. Thermochim Acta 2001, 380:123-151.
8. Takahashi A.I., Veiga F.J.B., Ferraz H.G. A literature review of cyclodextrin inclusion complexes characterization. Part II: X-ray diffraction, infrared spectroscopy and nuclear magnetic resonance. Int J Pharm Sci Rev Res 2012, 12:8-15.
9. Krois D., Brinker U.H. Circular dichroism of cyclodextrin complexes. Cyclodextrins and Their Complexes 2008, 289-298. Wiley-VCH Verlag, Weinheim, Germany. H. Dodziuk (Ed.).
10. Szente L., Szeman J. Cyclodextrins in analytical chemistry: host-guest type molecular recognition. Anal Chem 2013, 85:8024-8030.
11. Schneiderman E., Stalcup A.M. Cyclodextrins: a versatile tool in separation science. J Chromatogr B Biomed Sci Appl 2000, 745:83-102.
12. Szejtli J. Cyclodextrins and molecular encapsulation. Encyclopedia of Nanoscience and Nanotechnology 2004, 2:283-304. American Scientific Publishers, Stevenson Ranch, CA.
13. Loftsson T., Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007, 329:1-11.
14. Arima H., Higashi T., Motoyama K. Improvement of the bitter taste of drugs by complexation with cyclodextrins: applications, evaluations and mechanisms. Ther Deliv 2012, 3:633-644.
15. Laza-Knoerr A.L., Gref R., Couvreur P. Cyclodextrins for drug delivery. J Drug Target 2010, 18:645-656.
16. Cravotto G., Binello A., Baranelli E., et al. Cyclodextrins as food additives and in food processing. Curr Nutr Food Sci 2006, 2:343-350.
17. Duchene D., Bochot A., Loftsson T. Cyclodextrins and their use in pharmacy and cosmetology. STP Pharma Pratiques 2009, 19:15-27.
18. Gruiz K., Molnar M., Fenyvesi E., et al. Cyclodextrins in innovative engineering tools for risk-based environmental management. J Incl Phenom Macrocycl Chem 2011, 70:299-306.
19. Bar R. Applications of cyclodextrins in biotechnology. Comprehensive Supramolecular Chemistry, Volume 3: Cyclodextrins 1996, 423-440. Pergamon, Oxford, UK. J. Szejtli, T. Osa (Eds.).
20. Szente L., Szejtli J., Kis G.L. Spontaneous opalescence of aqueous γ-cyclodextrin solutions: complex formation or self-aggregation?. J Pharm Sci 1998, 87:778-781.
21. Perret F., Parrot-Lopez H. Amphiphilic cyclodextrins: synthesis and characterization. Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine 2011, 199-233. John Wiley and Sons, Hoboken, NJ. E. Bilensoy (Ed.).
22. Rajewski R.A., Stella V.J. Pharmaceutical applications of cyclodextrins. 2. Invivo drug delivery. J Pharm Sci 1996, 85:1142-1169.
23. Ueda H., Ou D., Endo T., et al. Evaluation of a sulfobutyl ether β-cyclodextrin as a solubilizing/stabilizing agent for several drugs. Drug Dev Ind Pharm 1998, 24:863-867.
24. Szente L., Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv Drug Delivery Rev 1999, 36:17-28.
25. Brewster M.E., Loftsson T. The use of chemically modified cyclodextrins in the development of formulations for chemical delivery systems. Pharmazie 2002, 57:94-101.
26. Fenyvesi É., Szemán J., Csabai K., et al. Methyl-beta-cyclodextrins: the role of number and types of substituents in solubilizing power. J Pharm Sci 2014, 103:1443-1452.
27. Higuchi T., Connors K.A. Phase-solubility techniques. Adv Anal Chem Instrum 1965, 4:117-212.
28. Fenyvesi É, Vikmon AM, Szente L. Cyclodextrins in Food Technology and Human Nutrition: Benefits and Limitations in 2012. Crit Rev Food Sci Nutr; [Epub ahead of print].
29. Nishijo J., Moriyama S., Shiota S. Interactions of cholesterol with cyclodextrins in aqueous solution. Chem Pharm Bull 2003, 51:1253-1257.
30. Irie T., Otagiri M., Sunada M., et al. Cyclodextrin-induced hemolysis and shape changes of human erythrocytes invitro. J Pharmacobiodyn 1982, 5:741-744.
31. Ohtani Y., Irie T., Uekama K., et al. Differential effects of α-, β- and γ-cyclodextrins on human erythrocytes. Eur J Biochem 1989, 186:17-22.
32. Motoyama K., Toyodome H., Onodera R., et al. Involvement of lipid rafts of rabbit red blood cells in morphological changes induced by methylated β-cyclodextrins. Biol Pharm Bull 2009, 32:700-705.
33. Kiss T., Fenyvesi F., Bácskay I., et al. Evaluation of the cytotoxicity of β-cyclodextrin derivatives: evidence for the role of cholesterol extraction. Eur J Pharm Sci 2010, 40:376-380.
34. Kiss T., Fenyvesi F., Pásztor N., et al. Cytotoxicity of different types of methylated β-cyclodextrins and ionic derivatives. Pharmazie 2007, 62:557-558.
35. Kilsdonk E.P., Yancey P.G., Stoudt G.W., et al. Cellular cholesterol efflux mediated by cyclodextrins. J Biol Chem 1995, 270:17250-17256.
36. Leroy-Lechat F., Wouessidjewe D., Andreux J.P., et al. Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives. Int J Pharm 1994, 101:97-103.
37. Salem L.B., Bosquillon C., Dailey L.A., et al. Sparing methylation of beta-cyclodextrin mitigates cytotoxicity and permeability induction in respiratory epithelial cell layers invitro. J Contr Rel 2009, 136:110-111.
38. Yancey P.G., Rodrigueza W.V., Kilsdonk E.P.C., et al. Cellular cholesterol efflux mediated by cyclodextrins. Demonstration of kinetic pools and mechanism of efflux. J Biol Chem 1996, 271:16026-16034.
39. Ostrom R.S., Liu X. Detergent and detergent-free methods to define lipid rafts and caveolae. Methods in Molecular Biology, Vol. 400: Methods in Membrane Lipids 2007, 459-468. Humana Press, Totowa, NJ. A.M. Dopico (Ed.).
40. Zidovetzki R., Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta 2007, 1768:1311-1324.
41. Kenworthy A.K. Fluorescence recovery after photobleaching studies of lipid rafts. Methods in Molecular Biology, Vol. 398: Lipid Rafts 2007, 179-192. Humana Press, Totowa, NJ. A.M. Dopico (Ed.).
42. Christian A.E., Haynes M.P., Phillips M.C., et al. Use of cyclodextrins for manipulating cellular cholesterol content. J Lipid Res 1997, 38:2264-2272.
43. Letoha T., Gaal S., Somlai C., et al. Investigation of penetratin peptides. Part 2. Invitro uptake of penetratin and two of its derivatives. J Peptide Sci 2005, 11:805-811.
44. Gniadecki R., Poumay Y. Lipid rafts and keratinocyte apoptosis: regulation via death receptors and Akt. Open Dermatol J 2009, 3:163-165.
45. Arima H., Yunomae K., Morikawa T., et al. Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-β-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. Pharm Res 2004, 21:625-634.
46. Fenyvesi F., Fenyvesi É., Szente L., et al. P-glycoprotein inhibition by membrane cholesterol modulation. Eur J Pharm Sci 2008, 34:236-242.
47. Burnham M.E., Esnault S., Roti Roti E.C., et al. Cholesterol selectively regulates IL-5 induced mitogen activated protein kinase signaling in human eosinophils. PLoS One 2014, 9:e103122.
48. Barenholz Y. Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications. Subcellular Biochemistry, Vol. 37: Membrane Dynamics and Domains 2004, 167-215. Kluwer Academic/Plenum Publishers, New York. P.J. Quinn (Ed.).
49. López C.A., de Vries A.H., Marrink S.J. Molecular mechanism of cyclodextrin mediated cholesterol extraction. PLoS Comput Biol 2011, 7:e1002020.
50. Combes G.B., Varner D.D., Schroeder F., et al. Effect of cholesterol on the motility and plasma membrane integrity of frozen equine spermatozoa after thawing. J Reprod Fertil Suppl 2000, 56:127-132.
51. Amidi F., Farshad A., Khor A.K. Effects of cholesterol-loaded cyclodextrin during freezing step of cryopreservation with TCGY extender containing bovine serum albumin on quality of goat spermatozoa. Cryobiology 2010, 61:94-99.
52. Moce E., Purdy P.H., Graham J.K. Treating ram sperm with cholesterol-loaded cyclodextrins improves cryosurvival. Animal Reprod Sci 2010, 118:236-247.
53. Deli M.A. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta 2009, 1788:892-910.
54. Dehouck M.P., Méresse S., Delorme P., et al. An easier, reproducible, and mass-production method to study the blood-brain barrier invitro. J Neurochem 1990, 54:1798-1801.
55. Cecchelli R., Dehouck B., Descamps L., et al. Invitro model for evaluating drug transport across the blood-brain barrier. Adv Drug Deliv Rev 1999, 36:165-178.
56. Tilloy S., Monnaert V., Fenart L., et al. Methylated β-cyclodextrin as P-gp modulators for deliverance of doxorubicin across invitro model of the blood-brain barrier. Biorg Med Chem Lett 2006, 16:2154-2157.
57. Monnaert V., Belbeder D., Fenart L., et al. Effect of γ- and hydroxypropyl-γ-cyclodextrins on the transport of doxorubicin across an invitro model of blood-brain barrier. J Pharmacol Exp Ther 2004, 311:1115-1120.
58. Gil E.S., Li J., Xiao H., et al. Quaternary ammonium β-cyclodextrin nanoparticles for enhancing doxorubicin permeability across theinvitro blood-brain barrier. Biomacromolecules 2009, 10:505-516.
59. Nonaka N., Farr S.A., Kageyama H., et al. Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins. J Pharmacol Exp Ther 2008, 325:513-519.
60. Jeulin H., Grancher N., Kedzierewicz F., et al. Invivo antiviral activity of ribavirin/alpha-cyclodextrin complex: evaluation on experimental measles virus encephalitis model in mice. Int J Pharm 2008, 357:148-153.
61. Jeulin H., Venard V., Carapito D., et al. Effective ribavirin concentration in mice brain using cyclodextrin as a drug carrier: evaluation in a measles encephalitis model. Antiviral Res 2009, 81:261-266.
62. Jeulin H., Grancher N., Kedzierewicz F., et al. Evaluation by Q-RTPCR of the efficacy of ribavirin complexed with beta-cyclodextrin against measles virus in a mouse encephalitis model. Pathol Biol (Paris) 2006, 54:541-544.
63. Ye Y., Sun Y., Zhao H., et al. A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery. Int J Pharm 2013, 458:110-117.
64. Brewster M.E., Estes K.S., Loftsson T., et al. Improved delivery through biological membranes. XXXL: Solubilization and stabilization of an estradiol chemical delivery system by modified beta-cyclodextrins. J Pharm Sci 1988, 77:981-985.
65. Anderson W.R., Simpkins J.W., Brewster M.E., et al. Brain-enhanced delivery of testosterone using a chemical delivery system complexed with 2-hydroxypropyl-β-cyclodextrin. Drug Des Deliv 1988, 2:287-298.
66. Pitha J., Gerloczy A., Olivi A. Parenteral hydroxypropyl cyclodextrins: intravenous and intracerebral administration of lipophiles. J Pharm Sci 1994, 83:833-837.
67. Anderson W.R., Simpkins J.W., Brewster M.E., et al. Evidence for prolonged suppression of stress-induced release of adrenocorticotropic hormone and corticosterone with a brain-enhanced dexamethasone-redox delivery system. Neuroendocrinology 1989, 50:9-16.
68. Yaksh T.L., Jang J.D., Nishiuchi Y., et al. The utility of 2-hydroxypropyl-β-cyclodextrin as a vehicle for the intracerebral and intrathecal administration of drugs. Life Sci 1991, 48:623-633.
69. Jang J., Yaksh T.L., Hill H.F. Use of 2-hydroxypropyl-β-cyclodextrin as an intrathecal drug vehicle with opioids. J Pharmacol Exp Ther 1992, 261:592-600.
70. Rodgers J., Jones A., Gibaud S., et al. Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. PLoS One 2011, 5:e1308.
71. Hristova-Kazmierski M.K., Horan P., Davis P., et al. A new approach to enhance bioavailability of biologically active peptides: conjugation of a δ opioid agonist to β-cyclodextrin. Bioorg Med Chem Lett 1993, 3:831-834.
72. 7 β-CD) carbamazepine complex: preparation, characterization, molecular modeling, and evaluation of invivo anti-epileptic activity. AAPS PharmSci Tech 2011, 12:1163-1175.
73. Monnaert V., Tilloy S., Bricout H., et al. Behavior of α-, β-, and γ-cyclodextrins and their derivatives on an invitro model of blood-brain barrier. J Pharmacol Exp Ther 2004, 310:745-751.
74. Dodelet-Devillers A., Cayrol R., van Horssen J., et al. Functions of lipid raft membrane microdomains at the blood-brain barrier. J Mol Med 2009, 87:765-774.
75. Hülper P., Veszelka S., Walter F.R., et al. Acute effects of short-chain alkylglycerols on blood-brain barrier properties of cultured brain endothelial cells. Br J Pharmacol 2013, 169:1561-1573.
76. Tewes B.J., Galla H.J. Lipid polarity in brain capillary endothelial cells. Endothelium 2001, 8:207-220.
77. Binkowski-Machut C., Hapiot F., Martin P., et al. How cyclodextrins can mask their toxic effects on the blood-brain barrier. Biorg Med Chem Lett 2006, 16:1784-1787.
78. Chaves C., Shawahna R., Jacob A., et al. Human ABC transporters at blood-CNS interfaces as determinants of CNS drug penetration. Curr Pharm Des 2014, 20:1450-1462.
79. Zhong Y., Hennig B., Toborek M. Intact lipid rafts regulate HIV-1 Tat protein-induced activation of the Rho signaling and upregulation of P-glycoprotein in brain endothelial cells. J Cereb Blood Flow Metab 2010, 30:522-533.
80. Pontikis C.C., Davidson C.D., Walkley S.U., et al. Cyclodextrin alleviates neuronal storage of cholesterol in Niemann-Pick C disease without evidence of detectable blood-brain barrier permeability. J Inherit Metab Dis 2013, 36:491-498.
81. Lambert D., O'Neill C.A., Padfield P.J. Depletion of Caco-2 cell cholesterol disrupts barrier function by altering the detergent solubility and distribution of specific tight-junction proteins. Biochem J 2005, 387:553-560.
82. Francis S.A., Kelly J.M., McCormack J., et al. Rapid reduction of MDCK cell cholesterol by methyl-β-cyclodextrin alters steady state transepithelial electrical resistance. Eur J Cell Biol 1999, 78:473-484.
83. Hamid K.A., Katsumi H., Sakane T., et al. The effects of common solubilizing agents on the intestinal membrane barrier functions and membrane toxicity in rats. Int J Pharm 2009, 379:100-108.
84. Takizawa Y., Kishimoto H., Nakagawa M., et al. Effects of pharmaceutical excipients on membrane permeability in rat small intestine. Int J Pharm 2013, 453:363-370.
85. Yunomae K., Arima H., Hirayama F., et al. Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett 2003, 536:225-231.
86. Misaka S., Müller F., Fromm M.F. Clinical relevance of drug efflux pumps in the gut. Curr Opin Pharmacol 2013, 13:847-852.
87. Varma M.V., Ambler C.M., Ullah M., et al. Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab 2010, 11:730-742.
88. Fenyvesi F., Réti-Nagy K., Bacsó Z., et al. Fluorescently labeled methyl-beta-cyclodextrin enters intestinal epithelial Caco-2 cells by fluid-phase endocytosis. PLoS One 2014, 9:e84856.
89. Loftsson T., Brewster M.E. Physicochemical properties of water and its effect on drug delivery. A commentary. Int J Pharm 2008, 354:248-254.
90. Pohl P., Saparov S.M., Antonenko Y.N. The size of the unstirred layer as a function of the solute diffusion coefficient. Biophys J 1998, 75:1403-1409.
91. Loftsson T., Konrádsdóttir F., Másson M. Influence of aqueous diffusion layer on passive drug diffusion from aqueous cyclodextrin solutions through biological membranes. Pharmazie 2006, 61:83-89.
92. Brewster M.E., Noppe M., Peeters J., et al. Effect of the unstirred water layer on permeability enhancement by hydrophilic cyclodextrins. Int J Pharm 2007, 342:250-253.
93. Mayer P., Karlson U., Christensen P.S., et al. Quantifying the effect of medium composition on the diffusive mass transfer of hydrophobic organic chemicals through unstirred boundary layers. Environ Sci Technol 2005, 39:6123-6129.
94. Gil E.S., Wu L., Xu L., et al. β-Cyclodextrin-poly(β-amino ester) nanoparticles for sustained drug delivery across the blood-brain barrier. Biomacromolecules 2012, 13:3533-3541.
95. Storer R.J., Butler P., Hoskin K.L., et al. A simple method, using 2-hydroxypropyl-β-cyclodextrin, of administering α-chloralose at room temperature. J Neurosci Methods 1997, 77:49-53.
96. Perrière N., Yousif S., Cazaubon S., et al. A functional invitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Brain Res 2007, 1150:1-13.
97. Watanabe Y., Matsumoto Y., Seki M., et al. Absorption enhancement of polypeptide drugs by cyclodextrins. I. Enhanced rectal absorption of insulin from hollow-type suppositories containing insulin and cyclodextrins in rabbits. Chem Pharm Bull (Tokyo) 1992, 40:3042-3047.
98. Shao Z., Li Y., Chermak T., et al. Cyclodextrins as mucosal absorption promoters of insulin. II. Effects of β-cyclodextrin derivatives on α-chymotryptic degradation and enteral absorption of insulin in rats. Pharm Res 1994, 11:1174-1179.
99. Dreyfuss J.M., Oppenheimer S.B. Cyclodextrins and cellular interactions. Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine: Current and Future Industrial Applications 2011, Chapter 15:287-295. John Wiley and Sons, Hoboken, NJ.
100. Van der Kuy P.H., Lohman J.J., Hooymans P.M., et al. Pharmacokinetics of intranasal formulations of dihydroergotamine. Br J Clin Pharmacol 1998, 46:623-626.
101. Merkus FWHM, inventor and assignee. Nasal melatonin compositions. US Patent 6,007,834.1998.
102. Kondo T., Nishimura K., Hirata M., et al. Effects of cyclodextrins on nasal absorption and analgesic activity of opioids in rats. Proceedings of the Eighth International Symposium on Cyclodextrins 1996, 387-390. Kluwer Academic Publishers, Dordrecht. J. Szejtli, L. Szente (Eds.).
103. Schipper N.G., Verhoef J.C., Romeijn S.G., et al. Methylated β-cyclodextrins are able to improve the nasal absorption of salmon calcitonin. Calcif Tissue Int 1995, 56:280-282.
104. Al Omaria M.M., Daraghmeha N.H., El-Barghouthib M.I., et al. Novel inclusion complex of ibuprofen tromethamine with cyclodextrins: physico-chemical characterization. J Pharm Biomed Anal 2009, 50:449-458.
105. Boulmedarat L., Bochot A., Lesieur S., et al. Evaluation of buccal methyl-β-cyclodextrin toxicity on human oral epithelial cell culture model. J Pharm Sci 2005, 94:1300-1309.
106. Hermens W.A., Belder C.W., Merkus J.M., et al. Intranasal administration of estradiol in combination with progesterone to oophorectomized women: a pilot study. Eur J Obstet Gynecol Reprod Biol 1992, 43:65-70.
107. Asai K., Morishita M., Katsuta H., et al. The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. Int J Pharm 2002, 246:25-35.
108. Cabral Marques H., Hadgraft J., Kellaway I.W. Studies of cyclodextrin inclusion complexes. I: The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int J Pharm 1990, 63:259-266.
109. Cabral Marques H., Hadgraft J., Kellaway I.W., et al. Studies of cyclodextrin inclusion complexes. III. The pulmonary absorption of β-, DM-β- and HP-β-cyclodextrin in rabbits. Int J Pharm 1991, 77:297-302.
110. Cabral Marques H., Hadgraft J., Kellaway I.W., et al. Studies of cyclodextrin inclusion complexes. IV: The pulmonary absorption of salbutamol from a complex with 2-hydroxypropyl-β-cyclodextrin in rabbits. Int J Pharm 1991, 77:303-307.
111. Cabral-Marques H., Almeida R. Optimisation of spray-drying process variables for dry powder inhalation (DPI) formulations of corticosteroid/cyclodextrin inclusion complexes. Eur J Pharm Biopharm 2009, 73:121-129.
112. Wall D.A., Marcello J., Pierdomenico D., et al. Administration as hydoxypropyl-β-cyclodextrin complexes does not slow rates of pulmonary drug absorption in rats. STP Pharma Sci 1994, 4:63-68.
113. Doan T.V., Grégoire N., Lamarche I., et al. A preclinical pharmacokinetic modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin. Eur J Pharm Sci 2013, 48:223-230.
114. Swiech O., Dutkiewicz P., Wójciuk K., et al. Cyclodextrin derivatives conjugated with aromatic moieties as pH-responsive drug carriers for anthracycline. J Phys Chem B 2013, 117:13444-13450.
115. Okamatsu A., Motoyama K., Onodera R., et al. Design and evaluation of folate-appended α, β-, and γ-cyclodextrins having a caproic acid as a tumor selective antitumor drug carrier invitro and invivo. Biomacromolecules 2013, 14:4420-4428.
116. Okamatsu A., Motoyama K., Onodera R., et al. Folate-appended β-cyclodextrin as a promising tumor targeting carrier for antitumor drugs invitro and invivo. Bioconjug Chem 2013, 24:724-733.
117. Moser K., Kriwet K., Naik A., et al. Passive skin penetration and its quantification invitro. Eur J Pharm Biopharm 2001, 52:103-112.
118. Korting H.C., Schäfer-Korting M. Carriers in the topical treatment of the skin. Handbook of Experimental Pharmacology, Vol. 197: Drug Delivery 2010, 435-468. Springer Verlag, Berlin. M. Schäfer-Korting (Ed.).
119. Fireman S., Toledano O., Neimann K., et al. A look at emerging delivery systems for topical drug products. Dermatol Ther 2011, 24:477-488.
120. Loftsson T., Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001, 225:15-30.
121. Chen Y., Wang M., Fang L. Biomaterials as novel penetration enhancers for transdermal and dermal drug delivery systems. Drug Deliv 2013, 20:199-209.
122. Guy R.H. Current status and future prospects of transdermal drug delivery. Pharm Res 1996, 13:1765-1769.
123. Hougeir F.G., Kircik L. A review of delivery systems in cosmetics. Dermatol Ther 2012, 25:234-237.
124. Vega E., Egea M.A., Garduno-Ramirez M.L., et al. Flurbiprofen PLGA-PEG nanospheres: role of hydroxy-β-cyclodextrin on exvivo human skin permeation and invivo topical anti-imflammatory efficacy. Colloids Surf B Biointerfaces 2013, 110:339-346.
125. Klang V., Matsko N., Zimmermann A.M., et al. Enhancement of stability and skin permeation by sucrose stearate and cylodextrins in progesterone nanoemulsions. Int J Pharm 2010, 393:152-160.
126. Uekama K., Adachi H., Irie T., et al. Improved transdermal delivery of prostaglandin E1 through hairless mouse skin: combined use of carboxymethyl-ethyl-β-cyclodextrin and penetration enhancers. J Pharm Pharmacol 1992, 44:119-121.
127. Yang J., Wiley C.J., Godwin D.A., et al. Influence of hydroxypropyl-β-cyclodextrin on transdermal penetration and photostability of avobenzone. Eur J Pharm Biopharm 2008, 69:605-612.
128. Shokri J., Hasanzadeh D., Ghanbarzadeh S., et al. The effect of β-cyclodextrin on percutaneous absorption of commonly used Eusolex sunscreens. Drug Res 2013, 63:591-596.
129. Loftsson T., Brewster M.E. Pharmaceutical application of cyclodextrins: basic science and product development. J Pharm Pharmacol 2010, 62:1607-1621.
130. Kawabata Y., Wada K., Nakatani M., et al. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm 2011, 420:1-10.
131. Brewster M.E., Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 2007, 59:645-666.
132. Sharma U.S., Balasubramanian S.V., Straubinger R.M. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J Pharm Sci 1995, 84:1223-1230.
133. Hamada H., Ishihara K., Masuoka N., et al. Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins. J Biosci Bioeng 2006, 102:369-371.
134. Bouquet W., Ceelen W., Fritzinger B., et al. Paclitaxel/beta-cyclodextrin complexes for hyperthermic peritoneal perfusion-formulation and stability. Eur J Pharm Biopharm 2007, 66:391-397.
135. Fenyvesi F., Kiss T., Fenyvesi É., et al. Randomly methylated β-cyclodextrin derivatives enhance taxol permeability through human intestinal epithelial Caco-2 cell monolayer. J Pharm Sci 2011, 100:4734-4744.
136. Agüeros M., Zabaleta V., Espuelas S., et al. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles. J Control Release 2010, 145:2-8.
137. Pitha J. Amorphous water-soluble derivatives of cyclodextrins: from test tube to patient. J Contr Rel 1987, 6:309-313.
138. Pitha J., Szente L. Rescue from hypervitaminosis A or potentiation of retinoid toxicity by different modes of cyclodextrin administration. Life Sci 1983, 32:719-723.
139. Carpenter T.O., Pettifor J.M., Russell R.M., et al. Severe hypervitaminosis A in siblings: evidence of variable tolerance to retinol intake. J Pediatr 1987, 111:507-512.
140. Bom A., Hope F., Rutherford S., et al. Preclinical pharmacology of sugammadex. J Crit Care 2009, 24:29-35.
141. Palanca J.M., Aguirre-Rueda D., Granell M.V., et al. Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary cultures. Int J Med Sci 2013, 10:1278-1285.
142. Akha A.S., Rosa J., Jahr J.S., et al. Sugammadex: cyclodextrins, development of selective binding agents, pharmacology, clinical development, and future directions. Anesthesiol Clin 2010, 28:691-708.
143. Schaller S.J., Fink H. Sugammadex as a reversal agent for neuromuscular block: an evidence-based review. Core Evid 2013, 8:57-67.
144. Stair A., Fernandez-Bustamante C. Sugammadex, the first selective relaxant binding agent for neuromuscular block reversal. Drugs Today 2012, 48:405-413.
145. Fuchs-Buder T., Meistelman C., Schreiber J.U. Is sugammadex economically viable for routine use?. Curr Opin Anaesthesiol 2012, 25:217-220.
146. Ottinger E.A., Kao M.L., Carrillo-Carrasco N., et al. Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr Top Med Chem 2014, 14:330-339.
147. Vance J.E., Karten B. Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin. J Lipid Res 2014, 55:1609-1621.
148. Davidson C.D., Ali N.F., Micsenyi M.C., et al. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 2009, 4:e6951.
149. Liu B., Li H., Repa J.J., et al. Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J Lipid Res 2008, 49:663-669.
150. Ward S., O'Donnell P., Fernandez S., et al. 2-hydroxypropyl-β-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease. Pediatr Res 2010, 68:52-56.
151. Camargo F., Erickson R.P., Garver W.S., et al. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci 2001, 70:131-142.
152. Aqul A., Liu B., Ramirez C.M., et al. Unesterified cholesterol accumulation in late endosomes/lysosomes causes neurodegeneration and isprevented by driving cholesterol export from this compartment. JNeurosci 2011, 31:9404-9413.
153. -/- mouse. Proc Natl Acad Sci USA 2009, 106:2377-2382.
154. Ramirez C.M., Liu B., Taylor A.M., et al. Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life. Pediat Res 2010, 68:309-315.
155. Maulik M., Ghoshal B., Kim J., et al. Mutant human APP exacerbates pathology in a mouse model of NPC and its reversal by a β-cyclodextrin. Hum Mol Genet 2012, 21:4857-4875.
156. Griffin L.D., Gong W., Verot L., et al. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 2004, 10:704-711.
157. Yao J., Ho D., Calingasan N.Y., et al. Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. J Exp Med 2012, 209:2501-2513.
158. Bar-On P., Rockenstein E., Adame A., et al. Effects of the cholesterol-lowering compound methyl-β-cyclodextrin in models of α-synucleinopathy. J Neurochem 2006, 98:1032-1045.
159. Modi G., Antonio T., Reith M., et al. Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of invivo efficacy of the parent molecule. J Med Chem 2014, 57:1557-1572.
160. Tao H.Q., Meng Q., Li M.H., et al. HP-β-CD-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemia-reperfusion injury in rats. Naunyn-Schmiedebers Arch Pharmacol 2013, 386:61-70.
161. Rivers J.R., Maggo S.D., Ashton J.C. Neuroprotective effect of hydroxypropyl-β-cyclodextrin in hypoxia-ischemia. Neuroreport 2012, 23:134-138.
162. Çirpanli Y., Allard E., Passirani C., et al. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int J Pharm 2011, 403:201-206.
163. Alizadeh D., Zhang L., Hwang J., et al. Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas. Nanomedicine 2010, 6:382-390.
164. Lahrech H., Perles-Barbacaru A.T., Aous S., et al. Cerebral blood volume quantification in a C6 tumor model using gadolinium per (3,6-anhydro) α-cyclodextrin as a new magnetic resonance imaging preclinical contrast agent. J Cereb Blood Flow Metab 2008, 28:1017-1029.
165. -/- mice without carrying cholesterol through the bloodstream. J Lipid Res 2012, 53:2331-2342.
166. Liu B., Ramirez C.M., Miller A.M., et al. Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestrated cholesterol as bile acid. J Lipid Res 2010, 51:933-944.
167. Song W., Wang F., Lotfi P., et al. 2-Hydroxypropyl-β-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapy. J Biol Chem 2014, 289:10211-10222.
168. Kamikawa M., Lei X.F., Fujiwara Y., et al. ACAT1-associated late endosomes/lysosomes significantly improve impaired intracellular cholesterol metabolism and the survival of Niemann-Pick type C mice. Acta Histochem Cytochem 2014, 47:35-43.
169. National Niemann Pick Disease Foundation. Accessed 16 September2014. http://www.nnpdf.org/cyclodextrin.html.
170. Krisanova N., Sivko R., Kasatkina L., et al. Neuroprotection by lowering cholesterol: a decrease in membrane cholesterol content reduces transporter-mediated glutamate release from brain nerve terminals. Biochim Biophys Acta 2012, 1822:1553-1561.
171. Abulrob A., Tauskela J.S., Mealing G., et al. Protection by cholesterol-extracting cyclodextrins: a role for N-methyl-D-aspartate receptor redistribution. J Neurochem 2005, 92:1477-1486.
172. Paton L., Bitoun E., Kenyon J., et al. A novel mouse model of a patient mucolipidosis II mutation recapitulates disease pathology. J Biol Chem 2014, 289:26709-26721.
173. Wang M.S., Boddapati S., Sierks M.R. Cyclodextrins promote protein aggregation posing risks for therapeutic applications. Biochem Biophys Res Commun 2009, 386:526-531.
174. Wahrle S.E., Jiang H., Parsadanian M., et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008, 118:671-682.
175. del Toro D., Xifró X., Pol A., et al. Altered cholesterol homeostasis contributes to enhanced excitotoxicity. J Neurochem 2010, 115:153-167.
176. Godinho B.M., Ogier J.R., Darcy R., et al. Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease. Mol Pharm 2013, 10:640-649.
177. Prior M., Lehmann S., Sy M.S., et al. Cyclodextrins inhibit replication of scrapie prion protein in cell culture. J Virol 2007, 81:11195-11207.
178. Sc accumulation and prion disease incubation time. Neurobiol Dis 2005, 18:282-285.
179. Ben Zirar S., Astier A., Muchow M., et al. Comparison of nanosuspensions and hydroxypropyl-β-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. Eur J Pharm Biopharm 2008, 70:649-656.
180. Schwartz S., Milatovic D., Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997, 97:663-665.
181. Schwartz S., Ruhnke P., Ribaud P., et al. Improved outcome in central nervous system aspergillosis, using voriconazole treament. Blood 2005, 106:2641-2645.
182. Elter T., Sieniawski M., Gossmann A., et al. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int J Antimicrob Agents 2008, 28:262-265.
183. Nguyen F.N., Kar J.K., Zakaria A., et al. Isolated central nervous system histoplasmosis presenting with ischemic pontine stroke and meningitis in an immune-competent patient. JAMA Neurol 2013, 70:638-641.
184. Kamberi P., Sobel R.A., Clemons K.V., et al. Comparison of itraconazole and fluconazole treatments in a murine model of coccoidal meningitis. Antimicrob Agents Chemother 2007, 51:998-1003.
185. Kaiser M., Azeredo F.J., UchÔa F.T., et al. Pre-clinical pharmacokinetics evaluation of an anticonvulsant candidate benzaldehyde semicarbazone free and included in β-cyclodextrin. Eur J Pharm Sci 2010, 39:355-362.
186. Beraldo H., Sinisterra R.D., Teixeira L.R., et al. An effective anticonvulsant prepared following a host-guest strategy that uses hydroxy-β-cyclodextrin and benzaldehyde semicarbazone. Biochem Biophys Res Commun 2002, 296:241-246.
187. Löscher W., Hönack D. Intravenous carbamazepine: comparison of different parenteral formulations in a mouse model of convulsive status epilepticus. Epilepsia 1997, 38:106-113.
188. Clark A.M., Kriel R.L., Leppik I.E., et al. Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia 2013, 54:1099-1105.
189. Clark A.M., Kriel R.L., Leppik I.E., et al. Intravenous topiramate: safety and pharmacokinetics following single dose in patients with epilepsy or migraines taking oral topiramate. Epilepsia 2013, 54:1106-1111.
190. van Axel Castelli V., Trivieri G., Zucchelli I., et al. Characterization of an inclusion complex between cladribine and 2-hydroxypropyl-β-cyclodextrin. J Pharm Sci 2008, 97:3897-3906.
191. Giovannonni G., Comi G., Cook S., et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010, 362:416-426.
192. Hughes L.M., Griffith R., Aitken R.J. The search for a topical dual action spermicide/microbicide. Curr Med Chem 2007, 14:775-786.
193. Karginov V. Cyclodextrin derivatives as anti-infectives. Curr Opin Pharmacol 2013, 13:717-725.
194. Toyama Y., Pais E., Meiselman H.J., et al. Effects of cyclodextrins on RBC aggregation and blood viscosity. Clin Hemorheol Microcirc 2007, 36:173-180.
195. Irie T., Fukunaga K., Garwood M.K., et al. Hydroxypropyl cyclodextrins in parenteral use. II: Effects on transport and disposition of lipids in rabbit and humans. J Pharm Sci 1992, 81:524-528.
196. Kim M.J., Hong J.Y., Lee K.E., et al. Effect of cholesterol depletion on interleukin-8 production in human respiratory epithelial cells. Allergy Asthma Immunol Res 2013, 5:402-408.
197. Roy K., Ghosh M., Pal T.K., et al. Cholesterol lowering drug may influence cellular immune response by altering MHC II function. J Lipid Res 2013, 54:3106-3115.
198. Fulop T., Le Page A., Garneau H., et al. Aging, immunosenescence and membrane rafts: the lipid connection. Longev Healthspan 2012, 1:6.
199. Fülöp T., Douziech N., Goulet A.C., et al. Cyclodextrin modulation of T lymphocyte signal transduction with aging. Mech Ageing Dev 2001, 122:1413-1430.
200. Motoyama K., Arima H., Nishimoto Y., et al. Involvement of CD14 in the inhibitory effects of dimethyl-α-cyclodextrin on lipopolysaccharide signaling in macrophages. FEBS Lett 2005, 579:1707-1714.
201. Arima H., Nishimoto Y., Motoyama K., et al. Inhibitory effects of novel hydrophilic cyclodextrin derivatives on nitric oxide production in macrophages stimulated with lipopolysaccharide. Pharm Res 2001, 18:1167-1173.
202. Nociari M.M., Lehmann G.L., Perez Bay A.E., et al. Beta cyclodextrins bind, stabilize, and remove lipofuscin bisretinoids from retinal pigment epithelium. Proc Natl Acad Sci USA 2014, 111:E1402-E1408.
203. Li Y.C., Park M.J., Ye S.K., et al. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol 2006, 168:1107-1118.
204. Raghu H., Sodadasu P.K., Malla R.R., et al. Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. BMC Cancer 2010, 10:647.
205. Zhang Q., Furukawa K., Chen H.H., et al. Metastatic potential of mouse Lewis lung cancer cells is regulated via ganglioside GM1 by modulating the matrix metalloprotease-9 localization in lipid rafts. J Biol Chem 2006, 281:18145-18155.
206. Motoyama K., Higashi T., Arima H. Design and evaluation of folate-appended methyl-β-cyclodextrin as an active pharmaceutical ingredient for cancer treatment. Cyclodextrin News 2014, 28:1-6.
207. Motoyama K., Higashi T., Arima H. Potential use of folate-appended methyl-β-cyclodextrin as a novel antitumor agent. Drug Deliv Syst 2013, 28:99-108.
208. Onodera R., Motoyama K., Okamatsu A., et al. Involvement of cholesterol depletion from lipid rafts in apoptosis induced by methyl-β-cyclodextrin. Int J Pharm 2013, 452:116-123.
209. Weisz P.B., Joullie M.M., Hunter C.M., et al. A basic compositional requirement of agents having heparin-like cell-modulating activities. Biochem Pharmacol 1997, 54:149-157.
210. Folkman J., Weisz P.B. Interdisciplinary challenges. Control of angiogenesis. Biocatalysis and Biomimetics. ACS Symposium Series 392 1989, 19-32. American Chemical Society, Washington, DC. J.D. Burrington, D.S. Clark (Eds.).
211. Folkman J., Weisz P.B., Joullie M.M., et al. Control of angiogenesis with synthetic heparin substitutes. Science 1989, 243:1490-1493.
212. Groeneboer S., Pastoureau P., Vignon E., et al. Cyclodextrin polysulphate protects articular cartilage in experimental lapine knee osteoarthritis. Osteoarthritis Cartilage 2008, 16:986-993.